Cure My Disease

Don't miss your cure!

 Log in / Sign up

New home device may cut lung Flare-Ups in bronchiectasis patients

NCT ID NCT07135284

Symptom relief Sponsor: Synchrony-Medical, Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 200 adults with bronchiectasis who use the LibAirty airway clearance system at home as part of their regular care. Researchers want to see how often lung flare-ups happen over a year. Participants fill out short questionnaires and have their medical records reviewed during routine clinic visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LibAirty airway clearance system (a device that helps clear mucus from the lungs)
What this could lead to
If successful, this study could show that using the LibAirty device at home helps reduce lung flare-ups and improves quality of life for people with bronchiectasis.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. The device is already prescribed as part of usual care, so the study cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with bronchiectasis who have been prescribed the LibAirty airway clearance system as part of their standard care. Participants will be identified and recruited from outpatient pulmonary or respiratory clinics affiliated with participating study sites.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have a radiological diagnosis of Bronchiectasis based on high resolution chest CT scan 2. Have bronchiectasis characterized by either: * Daily productive cough (as determined by a treating physician) * OR Available documentation from the last 12 months of 2 or more pulmonary exacerbations requiring antibiotic therapy 3. Be at age ≥ 21 years 4. Prescribed and receives the LibAirty system for home use 5. Be on a standard of care treatment plan that includes at least one physician encounter every 6 months 6. No change in treatment for Bronchiectasis in the 2-month period prior to enrollment 7. Signed informed consent Exclusion Criteria: 1. Inability to independently perform therapy with the LibAirty system as directed 2. Any other condition that, in the opinion of the PI, could jeopardize the safety of the subject or impact the validity of the study results. 3. Pregnancy or planned pregnancy during the expected duration of the trial (12 months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchiectasis adult are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchiectasis adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University School Of Medicine

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Medical University of South Carolina

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.